CoChat
Sign Up
Cited by 395Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapyCancer Treatment and Pharmacology

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

Monk, Bradley J., Herzog, Thomas J., Kaye, Stanley B., Krasner, Carolyn N., Vermorken, Jan B., Muggia, Franco M., Pujade-Lauraine, Eric, Lisyanskaya, Alla S., Makhson, Anatoly N., Rolski, Janusz, Gorbounova, Vera A., Ghatage, Prafull, Bidzinski, Mariusz, Shen, Keng, Ngan, Hextan Yuen-Sheung, Vergote, Ignace B., Nam, Joo-Hyun, Park, Youn Choi, Lebedinsky, Claudia A., Poveda, Andrés M.·2010·Journal of Clinical Oncology
DOI 10.1200/jco.2009.25.4037
Open this paper in CoChat — free account

Abstract

Purpose: The objective of this study was to compare the efficacy and safety of trabectedin plus pegylated liposomal doxorubicin (PLD) with that of PLD alone in women with recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy. Patients and Methods: Women ≥ 18 years, stratified by performance status (0 to 1 v 2) and platinum sensitivity, were randomly assigned to receive an intravenous infusion of PLD 30 mg/m 2 followed by a 3-hour infusion of trabectedin 1.1 mg/m 2 every 3 weeks or PLD 50 mg/m 2 every 4 weeks. The primary end point was progression-free survival (PFS) by independent radiology assessment. Results: Patients (N = 672) were randomly assigned to trabectedin/PLD (n = 337) or PLD (n = 335). Median PFS was 7.3 months with trabectedin/PLD v 5.8 months with PLD (hazard ratio, 0.79; 95% CI, 0.65 to 0.96; P = .0190). For platinum-sensitive patients, median PFS was 9.2 months v 7.5 months, respectively (hazard ratio, 0.73; 95% CI, 0.56 to 0.95; P = .0170). Overall response rate (ORR) was 27.6% for trabectedin/PLD v 18.8% for PLD (P = .0080); for platinum-sensitive patients, it was 35.3% v 22.6% (P = .0042), respectively. ORR, PFS, and overall survival among platinum-resistant patients were not statistically different. Neutropenia was more common with trabectedin/PLD. Grade 3 to 4 transaminase elevations were also more common with the combination but were transient and noncumulative. Hand-foot syndrome and mucositis were less frequent with trabectedin/PLD than with PLD alone. Conclusion: When combined with PLD, trabectedin improves PFS and ORR over PLD alone with acceptable tolerance in the second-line treatment of recurrent ovarian cancer.

Overview

Integrity signals

Registry

Crossref · 10.1200/jco.2009.25.4037

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 30 references

Research works printed but not linked: 2

  1. Takahashi N, 2001, Clin Cancer Res, 7, 3251
  2. Donald S, 2003, Cancer Res, 63, 5902

Cited by

Sorted by citations

Items 301–395 of 395

Related

See all

Metadata

Authors
Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., Gorbounova, V. A., Ghatage, P., Bidzinski, M., Shen, K., Ngan, H. Y.-S., Vergote, I. B., Nam, J.-H., Park, Y. C., Lebedinsky, C. A., & Poveda, A. M.
Affiliations
  • University of California, Irvine (US)
  • From the University of California at Irvine (UCI) and UCI Medical Center, Orange, CA; Columbia University College of Physicians and Surgeons; New York University Hospital, New York, NY; the Royal Marsden Hospital, Surrey, United Kingdom; Gillette Center for Women's Studies, Massachusetts General Hospital, Boston, MA; Antwerp University Hospital, Edegem; University Hospital, Leuven, Belgium; Université Paris Descartes, Assistance Publique Hôpitaux de Paris, Hôpital Hôtel-Dieu, Paris, France; SPBSIH City...
ORCID
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2010-07-01
Volume
28
Issue
19
Pages
3107-3114
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.2009.25.4037
OpenAlex
W2125064537
Cited by
395
References
30
Citations by year
2026: 2 · 2025: 4 · 2024: 9 · 2023: 10 · 2022: 17 · 2021: 25 · 2020: 18 · 2019: 13 · 2018: 25 · 2017: 41 · 2016: 26 · 2015: 32 · 2014: 37 · 2013: 40 · 2012: 37
FWCI
51.61
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords
trabectedin, pegylated liposomal doxorubicin, recurrent ovarian cancer, second-line chemotherapy, platinum-resistant ovarian cancer, platinum-sensitive ovarian cancer, progression-free survival, overall response rate, neutropenia, transaminase elevation, hand-foot syndrome, mucositis
MeSH terms
Trabectedin, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dioxoles, Doxorubicin, Drug Administration Schedule, Female, Humans, Leukopenia, Middle Aged, Neoplasm Recurrence, Local, Neutropenia, Ovarian Neoplasms, Polyethylene Glycols, Stomatitis, Multivariate Analysis, Treatment Outcome, Tetrahydroisoquinolines, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review